Skip to main content

Table 2 Cancer incidence density by diabetes and metformin using status

From: Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

Cancer type Taiwanese population Incidence Incidence density (95%CI) of study cohort (per 10,000 person-years)
   Non DM
(n = 10491)
DM without medication
(n = 8130)
DM without metformin
(n = 4327)
DM with metformin
(n = 11390)
Total cancer 49.9 46.0 (39.5-52.6)ab 97.6 (86.9-108)ac 91.7 (76.6-107)bd 44.8 (38.6-51.0)cd
   Male 59.3 50.3 (41.0-59.6)ab 122 (104-139)ac 107 (84.9-130)bd 47.7 (39.0-56.4)cd
   Female 41.2 41.0 (31.9-50.1)ab 75.7 (62.6-88.8)ac 74.0 (54.1-93.8)bd 41.2 (32.4-50.1)cd
Esophagus 1.14 2.94 (1.28-4.60) 5.14 (2.62-7.66) 4.03 (0.81-7.26) 4.78 (2.74-6.83)
   Male 2.09 3.63 (1.11-6.15) 7.45 (3.05-11.9) 5.09 (0.10-10.1) 5.83 (2.78-8.89)
   Female 0.20 2.13 (0.04-4.21) 3.05 (0.38-5.73) 2.84 (-1.10-6.78) 3.52 (0.91-6.13)
Stomach 2.64 3.91 (1.99-5.83) 5.14 (2.62-7.66) 6.71 (2.55-10.9) 5.46 (3.28-7.65)
   Male 3.49 3.63 (1.12-6.15) 6.78 (2.58-11.0) 8.90 (2.31-15.5) 4.58 (1.88-7.29)
   female 1.86 4.23 (1.30-7.17) 3.67 (0.73-6.60) 4.26 (-0.56-9.09) 6.53 (2.98-10.1)
Colorectal 7.31 7.07 (4.50-9.64)ab 19.8 (14.9-24.8)ac 17.4 (10.7-24.1)bd 6.83 (4.39-9.27)cd
   Male 8.63 6.78 (3.35-10.2)a 23.6 (15.8-31.4)ab 12.7 (4.83-20.6) 9.57 (5.66-13.5)b
   female 6.06 7.40 (3.53-11.3)a 16.4 (10.2-22.6)b 22.6 (11.6-33.7)ac 3.52 (0.91-6.12)bc
Liver 6.55 5.88 (3.53-8.23)ab 24.3 (18.8-29.7)ac 18.7 (11.8-25.7)b 10.2 (7.24-13.2)c
   Male 9.25 8.64 (4.76-12.5)ab 32.3 (23.2-41.4)ac 29.1 (17.2-41.0)bd 12.5 (8.01-16.9)cd
   Female 3.90 2.65 (0.33-4.98)a 17.0 (10.7-23.3)a 7.10 (0.88-13.3) 7.54 (3.72-11.3)
Pancreas 0.99 2.45 (0.93-3.96) 5.14 (2.62-7.66) 4.70 (1.22-8.18) 4.78 (2.74-6.83)
   Male 1.17 2.72 (0.54-4.90) 5.42 (1.67-9.18) 5.09 (0.10-10.1) 5.41 (2.47-8.36)
   female 0.81 2.13 (0.04-4.21) 4.88 (1.50-8.27) 4.26 (-0.56-9.09) 4.02 (1.24-6.81)
  1. † ICD-9-CM also incorporates the A-code for cancer which was used in Taiwan in ambulatory care settings before the year 2000. Total cancer (140-208/A08-A14), esophagus cancer (150/A090), stomach cancer (151/A091), colorectal cancer (153-154/A093-A094), liver cancer (155/A095), pancreas cancer (157/A096).
  2. ‡ Age-gender-standardized cancer incidence per 10,000 persons (95% confidence intervals) in the Taiwanese Cancer Registry Annual Report for 2007.
  3. a, b, c, d: Statistical significance was estimated by using the overlap rule for 95% CIs. Where there is the same superscript it means that there is significant difference between the two groups.
\